71 related articles for article (PubMed ID: 17980147)
1. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer.
Park JC; Chae YK; Son CH; Kim MS; Lee J; Ostrow K; Sidransky D; Hoque MO; Moon C
Biochem Biophys Res Commun; 2008 Jan; 365(2):221-6. PubMed ID: 17980147
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma.
Maat W; Beiboer SH; Jager MJ; Luyten GP; Gruis NA; van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1291-8. PubMed ID: 18385040
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer.
Gery S; Komatsu N; Kawamata N; Miller CW; Desmond J; Virk RK; Marchevsky A; Mckenna R; Taguchi H; Koeffler HP
Clin Cancer Res; 2007 Mar; 13(5):1399-404. PubMed ID: 17332281
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer: from single-gene methylation to methylome profiling.
Heller G; Zielinski CC; Zöchbauer-Müller S
Cancer Metastasis Rev; 2010 Mar; 29(1):95-107. PubMed ID: 20099008
[TBL] [Abstract][Full Text] [Related]
5. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer.
Luxen S; Belinsky SA; Knaus UG
Cancer Res; 2008 Feb; 68(4):1037-45. PubMed ID: 18281478
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
8. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis.
Suzuki M; Iizasa T; Nakajima T; Kubo R; Iyoda A; Hiroshima K; Nakatani Y; Fujisawa T
Ann Surg Oncol; 2007 Sep; 14(9):2636-42. PubMed ID: 17602269
[TBL] [Abstract][Full Text] [Related]
10. Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells.
Gao Z; Xu Z; Hung MS; Lin YC; Wang T; Gong M; Zhi X; Jablon DM; You L
Anticancer Res; 2009 Jun; 29(6):2025-30. PubMed ID: 19528461
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer.
Cinti C; Macaluso M; Giordano A
Oncogene; 2005 Sep; 24(38):5821-6. PubMed ID: 16044156
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.
Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA
Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850
[TBL] [Abstract][Full Text] [Related]
13. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer.
Liu Z; Zhao J; Chen XF; Li W; Liu R; Lei Z; Liu X; Peng X; Xu K; Chen J; Liu H; Zhou QH; Zhang HT
Lung Cancer; 2008 Oct; 62(1):15-22. PubMed ID: 18358560
[TBL] [Abstract][Full Text] [Related]
14. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
15. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer.
Hu XT; Zhang FB; Fan YC; Shu XS; Wong AH; Zhou W; Shi QL; Tang HM; Fu L; Guan XY; Rha SY; Tao Q; He C
Oncogene; 2009 Jul; 28(26):2466-75. PubMed ID: 19448674
[TBL] [Abstract][Full Text] [Related]
16. HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells.
Inamura K; Togashi Y; Ninomiya H; Shimoji T; Noda T; Ishikawa Y
Anticancer Res; 2008; 28(4B):2121-7. PubMed ID: 18751384
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors.
Dudley KJ; Revill K; Whitby P; Clayton RN; Farrell WE
Mol Cancer Res; 2008 Oct; 6(10):1567-74. PubMed ID: 18922972
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
19. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.
Tao Q; Fujimoto J; Men T; Ye X; Deng J; Lacroix L; Clifford JL; Mao L; Van Pelt CS; Lee JJ; Lotan D; Lotan R
J Natl Cancer Inst; 2007 Nov; 99(22):1668-82. PubMed ID: 18000218
[TBL] [Abstract][Full Text] [Related]
20. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins.
Lopez-Serra L; Ballestar E; Ropero S; Setien F; Billard LM; Fraga MF; Lopez-Nieva P; Alaminos M; Guerrero D; Dante R; Esteller M
Oncogene; 2008 Jun; 27(25):3556-66. PubMed ID: 18223687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
